Tag Archives: gene therapy

Understanding The Business Model Of Gene Therapy Companies – Peeling The Onion Back To Understand Why Time Matters
November 4, 2021

By Deanna Petersen and Holly May, Chief Business Officer and Chief Commercial Officer, respectively, of AVROBIO, as part of the From The Trenches feature of LifeSciVC Moving from traditional drug development and commercialization to gene therapy development and commercialization can

Leave a comment

Nurturing A Culture Of “Smart Speed” To Bring Gene Therapy To The World
June 23, 2020

By Deanna Petersen, chief business officer at AVROBIO, and Georgette Verdin, chief human resources officer at AVROBIO, as part of the From The Trenches feature of LifeSciVC. As we approach our 5th anniversary and surpass our 125th hire, we have

Leave a comment

Recipe For Managing Data Disclosure Successfully With Academic Partners: A Public Gene Therapy Company Perspective
March 24, 2020

This blog post was written by Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC. When AVROBIO went public in June 2018, I found myself on the steep end of an unexpected but interesting

Leave a comment

 Leave No Stone Unturned: A Pipeline Story
October 10, 2019

This blog was written by Deanna Petersen, CBO of AVROBIO (@dmp9818), as part of the From The Trenches feature of LifeSciVC. Building a leading gene therapy pipeline in under two years (and a lot of air miles): how to persevere

Leave a comment

Predicting The Next Dominoes to Fall in 2019
January 31, 2019

This post was written by Michael Gladstone, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. Today I will continue my time-honored January tradition of an optimistic blog post providing some bold predictions for the

Leave a comment

A Hat Trick Of Cell And Gene Therapy IPOs: Avro, Magenta, and Unum
June 28, 2018

Last week, AvroBio and Magenta Therapeutics priced their IPOs on the same night. Less than three months earlier, Unum Therapeutics priced its IPO. All three biotech companies are emerging leaders in the cell and gene therapy space, broadly defined. They

Leave a comment

We Saw It Coming In Pharma: Now Gene Therapy Is Biotech 2.0 For Rare Diseases
February 1, 2018

This blog was written by Deanna Petersen, Chief Business Officer of AvroBio, as part of the From The Trenches feature of LifeSciVC.   It seems so clear now: gene therapy is on a roll.  As 2017 came to a close, the

1 Comment

Living Medicines With Curative Intent: Small N’s Go Viral
November 7, 2017

The field of gene and cell therapy has witnessed an unprecedented few months, almost unimaginable only a few years ago. It’s worth pausing to reflect on some of the recent highlights: FDA approval of two chimeric antigen receptor (CAR) T-cell

Leave a comment

Standing On The Shoulders Of Stem Cell Gene Therapists: History, Hyperbole And Hope For The Future
July 7, 2016

This post was written by Jason Gardner, Atlas EIR and CEO of Magenta Therapeutics, as part of the From The Trenches feature of LifeSciVC. A new type of medicine was approved in Europe at the end of May that culminated

Leave a comment

Cell And Gene Therapy: An “Outside-In” Technology Evolution
November 12, 2015

The exciting renaissance in cell and gene therapy over the past five years has yielded some of the most innovative medical advances in the industry’s pipeline today.  There are now multiple stories of patients getting “cured” of rare diseases, responding

2 Comments